Brief: Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved

Minerva Neurosciences

21/10/2025 13:03

Oct 21 (Reuters) - Minerva Neurosciences Inc NERV.O:

MINERVA NEUROSCIENCES ANNOUNCES FINANCING OF UP TO $200 MILLION TO ADVANCE ROLUPERIDONE FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA THROUGH A PHASE 3 CONFIRMATORY TRIAL AND RESUBMISSION OF ITS NEW DRUG APPLICATION AND PREPARATION FOR US COMMERCIAL LAUNCH, IF APPROVED

MINERVA NEUROSCIENCES- FURTHER $40 MILLION PROCEEDS MAY BE RECEIVED CONNECTED WITH CASH EXERCISE OF TRANCHE B WARRANTS CONTINGENT ON REACHING MILESTONE

MINERVA NEUROSCIENCES INC - WILL INCREASE SIZE OF ITS BOARD OF DIRECTORS AND WILL APPOINT UP TO THREE DIRECTORS

MINERVA NEUROSCIENCES - EXPECTED TO BE SUFFICIENTLY FUNDED THROUGH CONFIRMATORY PHASE 3 TRIAL FOR ROLUPERIDONE & RESUBMISSION OF NDA TO FDA

Source text: ID:nGNX2vs7YH

Further company coverage: NERV.O

 ((Reuters.Briefs@thomsonreuters.com;))